Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Treasury Shares (2017 - 2025)

Autolus Therapeutics' Treasury Shares history spans 9 years, with the latest figure at $16250.0 for Q2 2025.

  • For Q2 2025, Treasury Shares fell 61.22% year-over-year to $16250.0; the TTM value through Jun 2025 reached $16250.0, down 61.22%, while the annual FY2024 figure was $32412.0, 72.16% down from the prior year.
  • Treasury Shares reached $16250.0 in Q2 2025 per AUTL's latest filing, roughly flat from $16250.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.1 million in Q4 2021 to a low of $16250.0 in Q1 2025.
  • Average Treasury Shares over 5 years is $199793.2, with a median of $41905.0 recorded in 2024.
  • Peak YoY movement for Treasury Shares: surged 162.57% in 2021, then plummeted 72.16% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $1.1 million in 2021, then crashed by 62.99% to $403331.0 in 2022, then plummeted by 71.13% to $116436.0 in 2023, then tumbled by 72.16% to $32412.0 in 2024, then crashed by 49.86% to $16250.0 in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Treasury Shares are $16250.0 (Q2 2025), $16250.0 (Q1 2025), and $32412.0 (Q4 2024).